Results 61 to 70 of about 552 (107)

Pharmacological advances in <i>Candida auris</i>: emerging antifungal mechanisms and next-generation therapeutic strategies. [PDF]

J Enzyme Inhib Med Chem
Hudu SA, Saadi N, Morad EA, Tahir A, Jimoh AO.   +4 more
europepmc   +1 more source

<i>TAC1b</i> mutation in <i>Candida auris</i> decreases manogepix susceptibility owing to increased <i>CDR1</i> expression. [PDF]

Antimicrob Agents Chemother
Hirayama T, Miyazaki T, Tanaka R, Kitahori N, Yoshida M, Takeda K, Ide S, Iwanaga N, Tashiro M, Takazono T, Izumikawa K, Yanagihara K, Makimura K, Tsukamoto K, Mukae H.   +14 more
europepmc   +1 more source

New approaches for cryptococcosis treatment and prevention-a systematic review. [PDF]

J Thorac Dis
Li YM, Chen Z, Zeng S, Ye F, Li ZT.
europepmc   +1 more source

The Four Critical Priority Fungi According to the World Health Organization and the Hope for New Therapies: A Focus on Cell Wall Antifungal Targets. [PDF]

J Fungi (Basel)
Marena GD, Carvalho GC, Magalhães MHC, Figueiredo JM, Ramos DH, Nosanchuk JD, Taborda CP.   +6 more
europepmc   +1 more source

Emerging antifungal resistance in Candida parapsilosis: the end of the innocence. [PDF]

NPJ Antimicrob Resist
Guinea J, Escribano P, Cadeau M, Lombardi L, Morio F.   +4 more
europepmc   +1 more source

Genomic Insights of <i>Candida krusei</i>, an Emerging Fungal Pathogen With Intrinsic Antifungal Resistance. [PDF]

Open Forum Infect Dis
Jain K, Wadhwa K, Malik M, Haque S, Prieto MA, Kaur H.   +5 more
europepmc   +1 more source

Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: An Evolving Clinical Paradigm. [PDF]

Diagnostics (Basel)
Morena R, Morrone HL, Serapide F, Russo A.   +3 more
europepmc   +1 more source

New Therapeutic Options for Fusariosis: A Patent Review (2008-2023). [PDF]

J Fungi (Basel)
Faccin ID, Salomé TM, de Almeida de Souza GH, da Costa Xavier L, Alves IA, Lima VCF, Lucini F, Simionatto S, Rossato L.   +8 more
europepmc   +1 more source

<i>Candida auris</i>: host interactions, antifungal drug resistance, and diagnostics. [PDF]

Microbiol Mol Biol Rev
Chowdhary A, Lionakis MS, Chauhan N.
europepmc   +1 more source

Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS). [PDF]

Clin Infect Dis
Hodges MR, Tawadrous M, Cornely OA, Thompson GR, Slavin MA, Maertens JA, Dadwal SS, Rahav G, Hazel S, Almas M, Jakate A, Pypstra R.   +11 more
europepmc   +1 more source